Clinical trial
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From…
NCT00285051 · Rafa Laboratories, Industry · Terminated
Key facts
| NCT number | NCT00285051 |
|---|---|
| Title | Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy |
| Official title | Study to Compare the Safety and Efficacy of 2 Different Doses of Inhaled D8-THC to Standard Therapy With Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy |
| Lead sponsor | Rafa Laboratories, Industry |
| Collaborators | Teva Branded Pharmaceutical Products R&D, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | inhaled delta-8-THC 300mcg or 600mcg per dose |
| Enrollment | 6 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Feb 1, 2006 |
| Last update posted | Dec 23, 2020 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: